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Prognostic significance and clinicopathological associations of
COX-2 SNP in patients with nonsmall cell lung cancer
Abstract
Background. To further improve the screening, diagnosis, and therapy of patients with nonsmall cell
lung cancer (NSCLC) additional diagnostic tools are urgently needed. Gene expression of
Cyclooxygenase-2 (COX-2) has been linked to prognosis in patients with NSCLC. The role of the
COX-2 926G>C Single Nucleotide Polymorphism (SNP) in patients with NSCLC remains unclear. The
aim of this study was to investigate the potential of the COX-2 926G>C SNP as a molecular marker in
this disease. Methods. COX-2 926G>C SNP was analyzed in surgically resected tumor tissue of 85
patients with NSCLC using a PCR-based RFLP technique. Results. The COX-2 926G>C SNP
genotypes were detected with the following frequencies: GG n = 62 (73%), GC n = 20 (23%), CC n = 3
(4%). There were no associations between COX-2 SNP genotype and histology, grading or gender
detectable. COX-2 SNP was significantly associated with tumor stage (P = .032) and lymph node status
(P = .016, Chi-square test). With a median followup of 85.9 months, the median survival was 59.7
months. There were no associations seen between the COX-2 SNP genotype and patients prognosis.
Conclusions. The COX-2 926G>C SNP is detectable at a high frequency in patients with NSCLC. The
COX-2 926G>C SNP genotype is not a prognostic molecular marker in this disease. However, patients
with the GC or CC genotype seem more susceptible to lymph node metastases and higher tumor stage
than patients with the GG genotype. The results suggest COX-2 926G>C SNP as a molecular marker for
lymph node involvement in this disease.
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Background. To further improve the screening, diagnosis, and therapy of patients with nonsmall cell lung cancer (NSCLC)
additional diagnostic tools are urgently needed. Gene expression of Cyclooxygenase-2 (COX-2) has been linked to prognosis in
patients with NSCLC. The role of the COX-2 926G>C Single Nucleotide Polymorphism (SNP) in patients with NSCLC remains
unclear. The aim of this study was to investigate the potential of the COX-2 926G>C SNP as a molecular marker in this disease.
Methods. COX-2 926G>C SNP was analyzed in surgically resected tumor tissue of 85 patients with NSCLC using a PCR-based
RFLP technique. Results. The COX-2 926G>C SNP genotypes were detected with the following frequencies: GG n = 62 (73%),
GC n = 20 (23%), CC n = 3 (4%). There were no associations between COX-2 SNP genotype and histology, grading or gender
detectable. COX-2 SNP was significantly associated with tumor stage (P = .032) and lymph node status (P = .016, Chi-square
test). With a median followup of 85.9 months, the median survival was 59.7 months. There were no associations seen between the
COX-2 SNP genotype and patients prognosis. Conclusions. The COX-2 926G>C SNP is detectable at a high frequency in patients
with NSCLC. The COX-2 926G>C SNP genotype is not a prognostic molecular marker in this disease. However, patients with the
GC or CC genotype seem more susceptible to lymph node metastases and higher tumor stage than patients with the GG genotype.
The results suggest COX-2 926G>C SNP as a molecular marker for lymph node involvement in this disease.
Copyright © 2009 Peter P. Grimminger et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
The smoking of tobacco is the most prevalent cause of lung
cancer, which is the leading cause of cancer mortality in
the world towards the end of the 20th century [1, 2]. Each
year approximately 200 000 new cases of lung cancer are
diagnosed in the United States, and there were over 160 000
lung cancer related deaths in 2008 [3]. The only treatment
to cure patients with nonsmall cell lung cancer (NSCLC) is
radical surgery, but the 5-year survival rate still remains poor.
However, the concept of individualized treatment based
on genetic diﬀerences among patients promises to provide
improved treatment outcomes. Thus, the molecular mecha-
nisms involved in carcinogenesis and pharmacogenetics have
to be studied so that tailored treatments can be discovered
and developed.
Inflammation has been recognized as a contributing
factor in pathogenesis of many cancers [4]. Epidemiologic
studies have shown that prolonged use of nonsteroidal anti-
inflammatory drugs (NSAIDs) reduces the risk of a variety
of cancers including lung cancer [5–8]. Cyclooxygenases
(COXs, also named prostaglandin endoperoxide synthases or
PTGSs) are the key enzymes in the conversion of arachidonic
acid to prostaglandin (PG) and other eicosanoids [9, 10].
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Two isoforms have been identified; COX-1 is consistently
expressed in nearly all cells whereas COX-2 is normally
undetectable but induced under circumstances such as
inflammation and cancer [11]. Overexpression of COX-2
has been reported in several cancers, such as colorectal
[12, 13], pancreatic [14], breast [15], esophageal [16], gastric
[17], lung [18, 19], and several other cancers [20–23].
Single nucleotide polymorphisms (SNPs) are common
in the human genetic pool, and there is growing evidence
suggesting that genetic polymorphisms play a role in the
variability of drug response and toxicity in patients. A
predictive value concerning the response to chemotherapy
treatment has been reported for certain genetic SNPs in
several tumors, for example, gastric cancer [24], breast
cancer, colorectal cancer [25–27], and lung cancer [28, 29].
Earlier studies have already shown that COX-2 SNPs have
an impact in promoter activity and therefore influence
the variability of response [30]. Papafili et al. reported a
transcription alteration of the COX-2 gene caused by the
COX-2 926G>C SNP in the promoter region and an increase
of the levels of C-reactive protein.
The COX-2 926G>C SNP has been investigated earlier
regarding a possible increased risk of developing NSCLC, but
no association could be found for this SNP [31]. No study
of COX-2 926G>C polymorphism and potential prognostic
significance in NSCLC cancer patients has been reported so
far. Hence the rationale for conducting this study was to
investigate a possible prognostic role of the COX 926G>C
SNP in NSCLC.
2. Material and Methods
2.1. Patients. 85 tumor specimens from NSCLC patients,
available from a previous prospective clinical trail of 103
consecutive patients [32], were included in this study. 65
patients were male (76%) and 20 female (24%) with the
median age of 62.4 years. Seventy-six (89%) of these patients
were smokers.
According to the International Union Against Cancer
(UICC) TNM classification [33], 42 patients (49%) were
tumor stage I, 18 patients (21%) stage II, and 25 patients
(30%) stage IIIA. 39 (46%) patients had squamous cell
carcinoma, 31 (36%) had adenocarcinoma, and 15 (18%)
had large cell carcinoma. All 85 patients underwent tho-
racic surgery, and the tumors were R0 resected. Patients
with histopathologic stage 3a tumors received postoperative
radiotherapy. Informed consent was obtained from each
patient.
The median followup was 85.9 months (range 63–
105), and no patient was lost to followup. Tissue for gene
expression analysis was obtained during surgery immedi-
ately after lung resection and before starting mediastinal
lymphadenectomy. The tissues were immediately frozen in
liquid nitrogen and stored at −80◦C. Six-micrometer frozen
sections were taken from blocks of tumor tissue. Starting
with the first section, every fifth section was routinely stained
with hematoxylin and eosin and evaluated histopathologi-
cally. Sections were pooled for analysis from areas estimated
to have at least 75% malignant cells.
The primary tumors were graded histopathologically as
well diﬀerentiated (G1, one patient), moderately diﬀerenti-
ated (G2, eighteen patients), and poorly diﬀerentiated (G3,
sixty-six patients).
2.2. DNA Extraction and Genotyping of the COX-2 926G>C
SNP. DNA was extracted from representative tumor sec-
tions using the QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany). The COX-2 926G>C polymorphism was analysed
in tumor tissue of 85 patients with NSCLC using a PCR-
based RFLP technique. Forward and reverse primers used
were as follows: 5′-CAT TTA GCG TCC CTG CAA AT-3′
and 5′-TAC CTT CAC CCC CTC CTT GT-3′. Briefly, an
approximately 2 ng DNA was added to a reaction volume
of 15 μL, containing 7.5 μL TaqMan Universal PCR Master
Mix, No AmpErase UNG, and 0.75 μL custom-designed
probe. Amplifications and determination of genotypes were
performed using an Applied Biosystems 7500 Real Time PCR
System as follows: 95◦C (10′), 45 cycles of 93◦C (15′′), and
60◦C (1′). PCR fragments were digested using 3 units of the
restriction enzyme AciI and separated on a 3% agarose gel. A
technician blinded for the clinical data performed PCR/RFLP
analyses. A random sample of 20% of each polymorphism
was repeated and showed 100% concordance.
2.3. Statistical Analysis. Statistical analyses were carried out
using SPSS for Windows (version 17.0). A χ2 test was used to
assess the association between categorical clinicopathologic
data and COX-2 926G>C SNP genotype. Hazard ratios were
used to calculate the relative risks of death. These calculations
were based on the Pike estimate, with the use of the observed
and expected number of events as calculated in the log-rank
test statistic. The log-rank test [34] and Kaplan-Meier plots
[35] were used to evaluate the association of genotypes and
overall survival. Multivariate analysis was performed with
the Cox proportional hazards regression model. Statistical
significance was interpreted as P < .05. All P-values reported
were based on two-sided tests.
3. Results
In the studied cohort, the COX-2 926G>C SNP genotypes
were detected with the following disposition: the wild type
(WT) GG in n = 62 (73%), the heterozygote SNP GC in
n = 20 (23%), and the homozygote SNP CC in n = 3 (4%).
No association between COX-2 926G>C SNP genotype
and histology was seen, even though the CC genotype (n =
3) was only found in squamous cell carcinoma patients.
Also, neither grading nor gender had any detectable
association with the COX-2 926G>C SNP. All three patients
with the genotype CC were male, but due to the small
number of the CC genotype there was no statistical sig-
nificance. Seventy six (89%) of the patients were smokers.
There was no association between smokers and diﬀerent
COX 926 polymorphisms. However, in nonsmokers, the
COX 926 polymorphism is more frequent than in smokers
with borderline significance (P = .42 Pearson χ2; P = .056
Fisher’s Exact Test) (Figure 1).
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Figure 1: Distribution of the COX-2 926G>C SNP and wild type in
smoker or nonsmoker. In nonsmoker a COX-2 926 polymorphism
is borderline significant and more frequent than in smokers (P =
.056 Fisher’s Exact Test).
The COX-2 926G>C SNP was significantly associated
with a higher tumor stage (P = .032, Pearson χ2 test)
(Figure 2). All three CC genotypes were stage IIIa, 5 CG
and 13 GG genotypes were stage II, and 7 CG and 35 GG
genotypes were found in stage I.
Also, associations were discovered in the COX-2 926G>C
polymorphism and the lymph node metastasis (P = .016, χ2
test) (Figure 3). The three patients with the CC genotype had
all lymph node metastasis, two were pN1 and one was pN2.
Fifteen out of 20 patients (75%) with the CG genotype had
lymph node metastasis. Six of these patients were pN1 and
seven pN2. Only 35% of the patients (22 of 62) with the GG
genotype were suﬀering from lymph node metastasis.
With a median followup of 85.9 months, the median
survival was 59.7 months (range 38–105 months). Neither
the log-rank test (Mantel-Cox) (P = .848) nor the Kaplan-
Meier plots (Figure 4) showed any prognostic significance for
the COX-2 926G>C SNP.
4. Discussion
The COX-2 pathway is important in cancer development
because it is involved in the regulation of various critical
cellular processes such as tumor progression, metastases,
angiogenesis, and chemotherapy resistance [36–39]. Elevated
COX-2 expression has been associated with poor prognoses
in lung [40–42] and other cancers, such breast [43], head
and neck [44], colon [45], and cervix carcinomas [46].
However, little is known about COX-2 single nucleotide
polymorphisms in NSCLC. In this study, we found that the
COX-2 926G>C SNP is detectable at a high frequency in
patients with NSCLC. We used PCR-based RFLP protocols
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Figure 2: Tumor stage and COX-2 926G>C SNP in NSCLC. The
COX-2 926G>C SNP was significantly associated with a higher
tumor stage (P = .032, Pearson χ2 test).
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Figure 3: Distribution of the COX-2 926G>C polymorphism
and lymph node status. The COX-2 926G>C polymorphism is
associated with a higher lymph node status (P = .016, χ2 test).
to analyze the COX-2 926 genotype and found that 73% of
the patients had the wild type genotype (GG), 23% were
heterozygote (GC) and 4% homozygote (CC) for the COX-2
926 polymorphism.
Several previous studies have examined the associations
of COX-2 polymorphisms and tumor diseases. In breast
cancer, the COX-2 169-GG genotype was associated with
increased risk [47], but the COX-2 926G>C SNP was
not [48], while some tenuous evidence was found for an
interaction between the C allele of the COX-2 8473 SNP with
NSAIDs to reduce risk for hormone receptor positive breast
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Figure 4: Kaplan-Meier cumulative survival plot for nonsmall cell
lung cancer patients with CC, CG, and GG COX-2 926G>C SNP.
The probability of survival was not statistically diﬀerent between
the diﬀerent genotypes.
cancer. In the case of NSCLC, it was suggested that the COX-
2 8473SNP is associated with an increased risk of developing
lung cancer [31] but COX-2 926G>C SNP was not, as already
mentioned in the introduction.
The association between smoking and the COX-2
926G>C SNP did not reach statistical significance in this
study but the trend suggests the need for further investigation
with larger numbers.
Although we did not find the COX-2 926G>C SNP to be a
prognostic marker for NSCLC, NSCLC patients with the GC
or CC genotype were apparently more susceptible to lymph
node metastases and higher tumor stage than patients with
the GG genotype, suggesting that the COX-2 926G>C SNP is
a molecular marker for lymph node involvement.
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